IRWD (Ironwood Pharmaceuticals) Institutional Ownership: 97.70% (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRWD Ironwood Pharmaceuticals Inc IRWD
65 GF Score
Price $4.18
GF Value $4.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ironwood Pharmaceuticals Institutional Ownership?

Ironwood Pharmaceuticals IRWD -4.35% 65 Institutional Ownership is 97.70% as of Aug. 20, 2026. GuruFocus rates IRWD with a GF Score™ of 65/100 and a GF Value™ of $4.55 (Fairly Valued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ironwood Pharmaceuticals's institutional ownership is 97.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ironwood Pharmaceuticals's Insider Ownership is 8.05%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ironwood Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 91.54%.

Ironwood Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Ironwood Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ironwood Pharmaceuticals Institutional Ownership Chart

Ironwood Pharmaceuticals Historical Data

The historical data trend for Ironwood Pharmaceuticals can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 33.29 34.37 36.35 37.12 38.22 43.40 43.38 43.75 44.54 46.25
IRWD
65GF Score
Ironwood Pharmaceuticals Inc IRWD
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ironwood Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 97.70% mean?
Ironwood Pharmaceuticals (IRWD) has a Institutional Ownership of 97.70% as of Aug. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Ironwood Pharmaceuticals and its competitors.
Is Ironwood Pharmaceuticals' Institutional Ownership too high?
Ironwood Pharmaceuticals' current Institutional Ownership is 97.70%. Overall, Ironwood Pharmaceuticals has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' Institutional Ownership compare to TLRY and AQST?
Ironwood Pharmaceuticals' Institutional Ownership of 97.70% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Ironwood Pharmaceuticals and its competitors. Ironwood Pharmaceuticals's current Institutional Ownership is 97.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (IRWD) is currently considered Fairly Valued. The stock's GF Value™ is $4.55, compared to a current price of $4.18 — trading 8.1% below its estimated fair value. The current Institutional Ownership is 97.70%. Ironwood Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Ironwood Pharmaceuticals (IRWD), the current Institutional Ownership is 97.70% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ironwood Pharmaceuticals (IRWD) Overvalued in 2026?

Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued. The current stock price of $4.18 is trading 8.1% below its estimated GF Value™ of $4.55. GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.

Key valuation signals for IRWD:

  • Institutional Ownership: 97.70%
  • GF Value™: $4.55 vs. price of $4.18 (8.1% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the IRWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ironwood Pharmaceuticals Business Description

Other Exchanges I76:Germany
Address 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score

Get the complete analysis for IRWD

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.18
Price
$4.55
GF Value